Physician profile
John Brett Ironside
NPI 1891727855
$9,673.37
in general payments reported to CMS, 2019-2025
29 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,851 · 2020: $406 · 2021: $534 · 2022: $645 · 2023: $1,468 · 2024: $2,005 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,237.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,051.53 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,287.07 | 2019-2023 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $1,072.91 | 2019-2025 | |
| Amgen INC. | $653.78 | 2019-2024 | Uplizna, Aimovig |
| Pfizer INC. | $366.14 | 2019-2025 | |
| Lilly USA, LLC | $340.30 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Lundbeck LLC | $280.44 | 2020-2024 | Vyepti |
| Emd Serono, INC. | $169.29 | 2019-2022 | |
| Genzyme Corporation | $165.81 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $161.20 | 2021 | |
| Amneal Pharmaceuticals LLC | $135.07 | 2023-2025 | Crexont, Rytary |
| Springworks Therapeutics, INC. | $124.92 | 2025 | Gomekli |
| Allergan, INC. | $114.59 | 2019-2021 | |
| Argenx US, INC. | $92.04 | 2024-2025 | Vyvgart Hytrulo |
| Genentech USA, INC. | $80.65 | 2024 | Ocrevus Zunovo, Ocrevus |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $78.45 | 2019-2025 | Ultomiris, Soliris |
| Biohaven Pharmaceutical Holding Company LTD. | $78.29 | 2022 | |
| Celgene Corporation | $59.43 | 2024 | Zeposia |
| Ucb, INC. | $54.52 | 2023-2024 | Rystiggo |
| Supernus Pharmaceuticals, INC. | $53.38 | 2019-2020 | |
| Csl Behring | $47.79 | 2019-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $39.36 | 2025 | Hyqvia |
| Biogen, INC. | $37.05 | 2024-2025 | Vumerity |
| Neurocrine Biosciences, INC. | $36.21 | 2022-2023 | Ingrezza |
| Neurelis, INC. | $29.03 | 2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $18.22 | 2023 | Xeomin |
| Ipsen Biopharmaceuticals, INC | $17.31 | 2025 | Dysport |
| Acadia Pharmaceuticals INC | $16.43 | 2023 | Nuplazid |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ironside listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.